Lung Cancer Diagnostics Market to Reach US$ 34.8 Bn by 2034, Driven by Rising Cancer Incidence and Diagnostic Technology Advancements

The global lung cancer diagnostics market is entering a strong growth phase, driven by the rising incidence of lung cancer, growing awareness of early diagnosis, and rapid advances in imaging and molecular diagnostic technologies. The industry was valued at US$ 15.1 Bn in 2023 and is projected to expand at a CAGR of 7.9% from 2024 to 2034, reaching more than US$ 34.8 Bn by the end of 2034.

Lung cancer affects cells lining the air passages and remains one of the leading causes of cancer-related deaths worldwide. The two major forms are non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Early detection is critical because timely diagnosis can significantly improve treatment options and patient outcomes. Common diagnostic approaches include CT scans, PET scans, chest X-rays, biopsies, blood tests, and molecular testing.

Access important conclusions and data points from our Report in this sample - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=74159

Key Drivers of Market Growth

The rise in lung cancer incidence remains the primary factor supporting market expansion. According to estimates cited by the World Cancer Research Fund International, more than 2 million new lung cancer cases were reported globally in 2022, making lung cancer the most commonly occurring cancer worldwide.
Tobacco consumption continues to be a major risk factor, while air pollution, occupational exposure to hazardous substances, radon, and population aging are also contributing to the disease burden. Importantly, lung cancer is not limited to smokers. The Lung Cancer Research Foundation estimated that approximately 20% of annual lung cancer diagnoses occur among people who have never smoked.

Another significant growth driver is technological advancement. Improvements in medical imaging, molecular diagnostics, liquid biopsy, biomarker discovery, and digital pathology are enabling faster and more accurate detection while reducing dependence on invasive procedures.

Key Players and Industry Leaders

The lung cancer diagnostics industry is fragmented, with established healthcare companies and specialized diagnostic technology providers competing through product innovation, partnerships, acquisitions, and R&D investments.
Prominent companies include Abbott, Bio-Rad Laboratories, Inc., Siemens Healthcare, GE HealthCare, Amoy Diagnostics Co., Boditech Med, Inc., Danaher, F. Hoffmann-La Roche, INOVIQ, MedGenome, Quest Diagnostics Incorporated, DiaSorin S.p.A., Oncocyte Corporation, QIAGEN, Thermo Fisher Scientific, Inc., NanoString Technologies, and Biodesix.

Companies are increasingly focusing on precision oncology, biomarker identification, highly sensitive mutation testing, AI-enabled pathology, and minimally invasive diagnostic solutions to strengthen their competitive positions.

Key Trends for the Future

One of the most important trends is the growing adoption of liquid biopsy. Unlike conventional tissue biopsy, liquid biopsy can analyze biomarkers in blood and other biological fluids, creating opportunities for less invasive cancer detection and monitoring.

AI-enabled imaging and digital pathology are also gaining momentum. Artificial intelligence can assist healthcare professionals in identifying suspicious lesions, analyzing pathology images, and improving diagnostic workflows.
For instance, in September 2024, Roche announced the expansion of its digital pathology open environment through the integration of more than 20 AI algorithms from eight new collaborators. These solutions are designed to provide pathologists with additional insights and support precision medicine.
Another emerging trend is the development of blood-based tests for assessing lung cancer risk. In October 2023, DELFI Diagnostics announced the commercial introduction of FirstLook Lung, a blood test based on fragmentomics, which analyzes characteristics of cell-free DNA fragments associated with cancer.

Visit our report for a deep dive into key insights and conclusions - https://www.transparencymarketresearch.com/lung-cancer-diagnostics-market.html

New Opportunities and Challenges

The increasing demand for non-invasive and personalized diagnostic methods is creating significant opportunities for market participants. New biomarkers, genomic testing, circulating tumor DNA analysis, circulating tumor cells, cell-free RNA, and exosome-based testing could broaden the diagnostic toolkit available to clinicians.

Localized and cost-effective molecular testing is another opportunity, particularly in emerging markets. In December 2023, Biofidelity announced the commercial launch of its ASPYRE-Lung RUO reagent product, designed to simplify and accelerate genomic biomarker detection.
However, high diagnostic costs remain a major restraint. Advanced imaging systems, molecular tests, laboratory infrastructure, and specialized expertise can make sophisticated diagnostics inaccessible in some regions. Limited healthcare infrastructure and uneven access to cancer screening also present challenges, particularly across low- and middle-income countries.

Market Trends & Innovations

Innovation is increasingly centered on improving diagnostic accuracy, shortening turnaround times, and reducing invasiveness. Robotic-assisted bronchoscopy is one notable development, enabling physicians to access difficult-to-reach lung nodules and perform targeted biopsies.
North America remains a leading regional market due to advanced healthcare infrastructure, high awareness, strong R&D activity, and increasing adoption of innovative diagnostic technologies. In the U.S., robotic-assisted systems and AI-based pathology are helping improve diagnostic workflows.
In July 2021, USA Health Mitchell Cancer Institute introduced the Auris Health Monarch robotic system for advanced lung cancer diagnosis. The technology supports visualization and biopsy of hard-to-reach lung nodules, demonstrating the growing role of robotic technologies in pulmonary diagnostics.
International initiatives are also supporting diagnostic capacity building. In July 2022, the International Atomic Energy Agency partnered with GE HealthCare under its Rays of Hope initiative to train radiologists and nuclear medicine professionals in Africa and Latin America.

Future Outlook

The lung cancer diagnostics market is expected to maintain strong momentum through 2034 as healthcare systems place greater emphasis on early detection and precision medicine. The combination of rising disease prevalence, technological innovation, growing screening awareness, and expanding molecular testing is likely to create new commercial opportunities.
Future growth is expected to be shaped by AI-powered diagnostics, liquid biopsy, genomic profiling, biomarker discovery, robotic bronchoscopy, and integrated digital pathology platforms. Companies that successfully deliver accurate, rapid, affordable, and minimally invasive diagnostic solutions are likely to gain a competitive advantage.

Buy this Premium Research Report and gain expert perspectives and analysis - https://www.transparencymarketresearch.com/checkout.php?rep_id=74159<ype=S

Market Segmentation

The global lung cancer diagnostics market can be segmented as follows:

By Diagnostic Test Type:
Biopsy, including needle biopsy, transbronchial biopsy, thoracoscopic biopsy, and other approaches; liquid biopsy, including circulating tumor cells (CTCs), circulating tumor DNA, cell-free RNA, exosomes, and proteomic analysis; imaging tests, including MRI, CT scan, chest ultrasound, PET, and other imaging tests; molecular testing; and other diagnostic methods such as sputum cytology and pulmonary function tests.

By Product Type:
Instruments and consumables.

By Cancer Type:
Non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).

By End-user:
Hospitals, clinics, diagnostic and imaging centers, and cancer research institutes.

By Region:
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

Important FAQs

What was the size of the global lung cancer diagnostics market in 2023?
The global lung cancer diagnostics market was valued at US$ 15.1 Bn in 2023.

What will be the size of the lung cancer diagnostics market by 2034?
The market is projected to cross US$ 34.8 Bn by the end of 2034.

What CAGR is expected during the forecast period?
The market is anticipated to expand at a CAGR of 7.9% from 2024 to 2034.

Which region is expected to hold a major market share?
North America is expected to account for a leading share of the global market during the forecast period.

Who are the prominent companies in the lung cancer diagnostics market?
Major participants include Abbott, Bio-Rad Laboratories, Siemens Healthcare, GE HealthCare, Amoy Diagnostics, Boditech Med, Danaher, F. Hoffmann-La Roche, INOVIQ, MedGenome, Quest Diagnostics, DiaSorin, Oncocyte, QIAGEN, Thermo Fisher Scientific, NanoString Technologies, and Biodesix.

More Trending Reports by Transparency Market Research -

Autoimmune Disease Diagnostics Market: https://www.transparencymarketresearch.com/autoimmune-disease-diagnostics-market.html

In Vitro Diagnostics Market: https://www.transparencymarketresearch.com/in-vitro-diagnostics-market.html

Multiplexed Diagnostics Market: https://www.transparencymarketresearch.com/multiplexed-diagnostics-market.html

Companion Diagnostics Market: https://www.transparencymarketresearch.com/companion-diagnostics-market.html

About Transparency Market Research
Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Media Contact:
Abhishek Budholiya
Transparency Market Research Inc.
State Tower, 90 State Street, Suite 700,
Albany NY - 12207, United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Sales Inquiries: sales@transparencymarketresearch.com
Media Inquiries: media@transparencymarketresearch.com

This release was published on openPR.